Pfizer and Eisai Will Continue Aricept Deal, But Add Lyrica To The Agreement
This article was originally published in PharmAsia News
Executive Summary
A potential sticking point in Pfizer's acquisition of Wyeth has been resolved - the big drug maker and Eisai have agreed to continue co-promoting Aricept (donepezil) in the U.S., Europe and Japan. However, Eisai will regain full Japanese rights to the Alzheimer's blockbuster at the end of 2012, while the rest of the collaboration will remain in place until 2022
You may also be interested in...
Eisai And Pfizer Begin Undertaking To Switch Appropriate Patients To High-dose Aricept
TOKYO - Eisai will launch a "substantial marketing campaign" behind the recent U.S. approval of high-dose Aricept (donepezil) as the company races to move moderate to severe Alzheimer's disease patients that could benefit from higher doses of the drug from the 10 mg dosage to the newly approved 23 mg dosage ahead of Aricept 10 mg's November 2010 patent loss
Eisai And Pfizer Begin Undertaking To Switch Appropriate Patients To High-dose Aricept
TOKYO - Eisai will launch a "substantial marketing campaign" behind the recent U.S. approval of high-dose Aricept (donepezil) as the company races to move moderate to severe Alzheimer's disease patients that could benefit from higher doses of the drug from the 10 mg dosage to the newly approved 23 mg dosage ahead of Aricept 10 mg's November 2010 patent loss
New Licensing Models For New Markets - BIO Conference
CHICAGO - Whether or not the world is flat, licensing deals are no longer simply a transfer of global rights, and pharma companies are trying to determine how best to carve up regional rights and how to coordinate marketing efforts